@article{3ef5ab8c019c48b1b83ce996e8fd4ed3,
title = "Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use",
keywords = "asthma, asthma treatment, biologics, eosinophils",
author = "Albers, {Frank C.} and Soichiro Hozawa and Bratton, {Daniel J.} and Yancey, {Steven W.} and Prazma, {Charlene M.} and Marc Humbert and Liu, {Mark C.}",
note = "Funding Information: This analysis (GSK ID: 208116) and the original MENSA and MUSCA studies (GSK ID: MEA115588/NCT01691521, and GSK ID: 200862/NCT02281318, respectively) were funded by GSK. Funding Information: Editorial support (in the form of writing assistance, including development of the initial draft from the source data, assembling tables and figures, collating authors comments, grammatical editing and referencing) was provided by Elizabeth Hutchinson PhD, CMPP, at Fishawack Indicia Ltd, UK, and was funded by GSK. ",
year = "2020",
month = apr,
day = "1",
doi = "10.1111/all.14048",
language = "English (US)",
volume = "75",
pages = "942--946",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "4",
}